Table 2. Effect of doxorubicin and ZnO NPs on the reproductive performance parameters.
| Groups | Sperm cell count (×106 ml–1) | Sperm motility (%) | Sperm viability (%) | Sperm abnormalities (%) | Testosterone (ng ml–1) |
| G1 (Control) | 301.55 ± 1.32b | 88.50 ± 1.06b | 90.56 ± 1.32b | 12.00 ± 0.04b | 3.28 ± 0.43b |
| G2 (ZnO NPs) | 425.15 ± 2.24a | 95.75 ± 1.86a | 96.75 ± 1.44a | 10.15 ± 0.60b | 5.27 ± 0.34a |
| G3 (Doxorubicin) | 106.86 ± 1.94d | 50.00 ± 2.16d | 55.20 ± 2.42d | 24.60 ± 0.86a | 1.87 ± 0.26d |
| G4 (Doxorubicin + ZnO NPs) | 225.00 ± 1.81c | 78.33 ± 1.96c | 83.11 ± 1.96c | 15.95 ± 0.74ab | 2.84 ± 0.64c |